New York State Teachers Retirement System Has $11.82 Million Stock Holdings in Neurocrine Biosciences, Inc. $NBIX

New York State Teachers Retirement System decreased its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 6.2% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 89,710 shares of the company’s stock after selling 5,921 shares during the quarter. New York State Teachers Retirement System owned 0.09% of Neurocrine Biosciences worth $11,818,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently bought and sold shares of the business. USA Financial Formulas acquired a new stake in Neurocrine Biosciences during the 4th quarter worth about $25,000. Geneos Wealth Management Inc. increased its holdings in shares of Neurocrine Biosciences by 143.6% in the 1st quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock valued at $25,000 after purchasing an additional 135 shares during the period. DJE Kapital AG acquired a new position in shares of Neurocrine Biosciences in the 4th quarter valued at about $28,000. Meeder Asset Management Inc. lifted its position in shares of Neurocrine Biosciences by 651.6% in the fourth quarter. Meeder Asset Management Inc. now owns 233 shares of the company’s stock worth $33,000 after purchasing an additional 202 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd purchased a new stake in shares of Neurocrine Biosciences in the fourth quarter worth approximately $39,000. 92.59% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, insider Darin Lippoldt sold 9,800 shares of the company’s stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $170.16, for a total transaction of $1,667,568.00. Following the completion of the sale, the insider owned 54,729 shares in the company, valued at approximately $9,312,686.64. This represents a 15.19% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Leslie V. Norwalk sold 1,250 shares of the stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $168.06, for a total value of $210,075.00. Following the transaction, the director directly owned 2,838 shares in the company, valued at approximately $476,954.28. This represents a 30.58% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 365,234 shares of company stock valued at $57,031,540. 4.60% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research analysts recently commented on NBIX shares. Wedbush boosted their price objective on shares of Neurocrine Biosciences from $166.00 to $176.00 and gave the company an “outperform” rating in a research report on Wednesday, May 6th. Morgan Stanley increased their target price on shares of Neurocrine Biosciences from $185.00 to $191.00 and gave the stock an “equal weight” rating in a research report on Wednesday, May 6th. Sanford C. Bernstein initiated coverage on shares of Neurocrine Biosciences in a research note on Friday, May 22nd. They set an “outperform” rating and a $221.00 target price for the company. Royal Bank Of Canada boosted their price target on shares of Neurocrine Biosciences from $180.00 to $183.00 and gave the company an “outperform” rating in a report on Friday, May 29th. Finally, Canaccord Genuity Group upped their price target on shares of Neurocrine Biosciences from $164.00 to $200.00 and gave the stock a “buy” rating in a research note on Tuesday, April 7th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $187.52.

Neurocrine Biosciences Price Performance

Neurocrine Biosciences stock opened at $174.26 on Monday. The company has a market capitalization of $17.52 billion, a price-to-earnings ratio of 26.85, a PEG ratio of 0.69 and a beta of 0.39. Neurocrine Biosciences, Inc. has a one year low of $122.14 and a one year high of $174.38. The company’s fifty day moving average price is $155.99 and its two-hundred day moving average price is $141.73.

About Neurocrine Biosciences

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.